Guselkumab shows minor added benefit for specific Crohn’s disease patients

Post author:admin
Post published:March 27, 2026
Post category:uncategorized

The human monoclonal antibody guselkumab has been approved for certain adults with moderately to severely active ulcerative colitis since April 2025.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Global analysis uses machine learning to map drivers of cancer outcomes

Beckman Coulter Life Sciences and Pillar Biosciences announce NGS application development pipeline for the Biomek NGeniuS System

Online resource launched to empower people with vulval lichen sclerosus

Helpful Links

Subscribe To Us